Close Menu

droplet microfluidics

The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.

Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.

The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.

Codefendant 1Cellbio, an instrument maker that had obtained a co-exclusive license to the patents, said it plans to appeal the court's declaration.

These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.

10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.

The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.

The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.

The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.

The company is currently looking for beta customers to test the system for whole-genome sequencing, exome sequencing, and RNA-seq library prep workflows.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.